1
|
Guo H, Zhao Y, Mu R, Zhang G, Chen S, Cao X, Liu K, Liu Y, Dai B, Zhou Y, Wang C, Yang J. The Protective Effect of Chronic Intermittent Hypobaric Hypoxia on Preventing the Destruction of CD34 + Haematopoietic Stem Cells in Aplastic Anaemia by Modulating the Th1/Th2 Balance. Stem Cell Rev Rep 2024; 20:301-312. [PMID: 37831395 DOI: 10.1007/s12015-023-10631-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/11/2023] [Indexed: 10/14/2023]
Abstract
Aplastic anaemia (AA) is a haematopoietic disorder caused by immune-mediated attack on haematopoietic stem cells (HSCs). Stem cell transplantation and immunosuppressive therapy remain the major treatment choice for AA patients but have limited benefits and undesired side effects. The aim of our study was to clarify the protective role of immunity of chronic intermittent hypobaric hypoxia (CIHH) and the underlying mechanism in AA. Our integrative analysis demonstrated that CIHH pre-treatment significantly improved haematopoiesis and survival in an AA rat model. We further confirmed that CIHH pre-treatment was closely associated with the Th1/Th2 balance and a large number of negative regulatory haematopoietic factors, such as TNF-α and IFN-γ, produced by hyperactive Th1 lymphocytes released in AA rats, which induced the death program in a large number of CD34+ HSCs by activating the Fas/FasL apoptosis pathway, while CIHH pre-treatment effectively downregulated the expression of TNF-α and IFN-γ, resulting in a reduction in Fas antigen expression in CD34+ HSCs. In summary, this study provides evidence that CIHH has good protective effect against AA by modulating immune balance in Th1/Th2 cells and may provide a new therapeutic strategy.
Collapse
Affiliation(s)
- Hui Guo
- Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Hangzhou, China
- Key Laboratory of Infection and Immunity of CAS, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
| | - Yilin Zhao
- Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Hangzhou, China
- Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, China
| | - Rui Mu
- College of Basic Medicine, Hebei Medical University, Shijiazhuang, China
| | - Guangdao Zhang
- Department of Prosthodontics, School of Stomatology, China Medical University, Shenyang, China
| | - Shuxian Chen
- College of Basic Medicine, Hebei Medical University, Shijiazhuang, China
| | - Xinwei Cao
- College of Basic Medicine, Hebei Medical University, Shijiazhuang, China
| | - Kangcan Liu
- College of Basic Medicine, Hebei Medical University, Shijiazhuang, China
| | - Yiran Liu
- College of Basic Medicine, Hebei Medical University, Shijiazhuang, China
| | - Baiyun Dai
- Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Hangzhou, China
- Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, China
| | - Yuan Zhou
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
| | - Chuan Wang
- Department of Pharmacology, Hebei Medical University, Shijiazhuang, China.
| | - Jing Yang
- Key Laboratory of Aging and Cancer Biology of Zhejiang Province, Hangzhou, China.
- Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, China.
| |
Collapse
|
2
|
Short treatment of peripheral blood cells product with Fas ligand using closed automated cell processing system significantly reduces immune cell reactivity of the graft in vitro and in vivo. Bone Marrow Transplant 2022; 57:1250-1259. [PMID: 35538142 PMCID: PMC9088133 DOI: 10.1038/s41409-022-01698-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 04/14/2022] [Accepted: 04/26/2022] [Indexed: 11/08/2022]
Abstract
Mobilized peripheral blood cells (MPBCs) graft and peripheral blood cells apheresis are used for bone marrow transplantation and for treatment of graft versus host disease (GvHD). We demonstrate that a short treatment of MPBCs with Fas ligand (FasL, CD95L) for 2 h using a closed automated cell processing system selectively induces apoptosis of specific donor T cells, B cells and antigen presenting cells, but, critically, not CD34+ hematopoietic stem cells and progenitors, all of which may contribute to an increased likelihood of graft survival and functionality and reduced GvHD. Treated cells secreted lower levels of interferon-gamma as compared with control, untreated, cells. Moreover, FasL treatment of immune cells increased signals, which led to their phagocytosis by activated macrophages. FasL treated immune cells also reduced the ability of activated macrophages to secrete pro-inflammatory cytokines. Most importantly, FasL ex vivo treated MPBCs prior to transplantation in NOD-SCID NSG mice prevented GvHD and improved stem cell transplantation in vivo. In conclusion, MPBCs, as well as other blood cell products, treated with FasL by automated manufacturing (AM), may be used as potential treatments for conditions where the immune system is over-responding to both self and non-self-antigens.
Collapse
|